Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 8/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.81 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.81 |
| ▸ | TSHR | P16473 | 5/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | S100B | P04271 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8954009 | 0.93 | CYP3A4 (0.94) | CYP3A4ALDH1A1TDP1TSHRSMN1; SMN2 | |
| Orthotolidine SCHEMBL49414 | 0.90 | CYP3A4 (1.00) | CYP3A4ALDH1A1TDP1TSHRSMN1; SMN2 | |
| Orthotolidine SCHEMBL29386552 | 0.90 | CYP3A4 (1.00) | CYP3A4ALDH1A1TDP1TSHRSMN1; SMN2 | |
| Orthotolidine SCHEMBL29365329 | 0.90 | CYP3A4 (1.00) | CYP3A4ALDH1A1TDP1TSHRSMN1; SMN2 | |
| Orthotolidine SCHEMBL867121 | 0.87 | CYP3A4 (0.94) | CYP3A4ALDH1A1TDP1TSHRSMN1; SMN2 | |
| Orthotolidine SCHEMBL11189493 | 0.87 | CYP3A4 (0.94) | CYP3A4ALDH1A1TDP1TSHRSMN1; SMN2 | |
| Orthotolidine SCHEMBL38664709 | 0.87 | CYP3A4 (0.94) | CYP3A4ALDH1A1TDP1TSHRSMN1; SMN2 | |
| Orthotolidine SCHEMBL20547383 | 0.87 | CYP3A4 (0.94) | CYP3A4ALDH1A1TDP1TSHRSMN1; SMN2 | |
| Orthotolidine SCHEMBL22129692 | 0.87 | CYP3A4 (0.94) | CYP3A4ALDH1A1TDP1TSHRSMN1; SMN2 | |
| Orthotolidine SCHEMBL2812115 | 0.87 | CYP3A4 (0.94) | CYP3A4ALDH1A1TDP1TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1620102-B1 | 3-(1-NAPHTHYL)-2-CYANOPROPANOIC ACID DERIVATIVES AS ESTROGEN RECEPTOR LIGANDS | WYETH CORP (US) | 2008-12-24 | — | — | EP | claimed |
| US-20070299105-A1 | 2-Cyanopropanoic Acid Amide and Ester Derivatives and Methods of Their Use | WYETH (US) | 2007-12-27 | — | — | US | claimed |
| EP-1620102-A2 | 3-(1-NAPHTHYL)-2-CYANOPROPANOIC ACID DERIVATIVES AS ESTROGEN RECEPTOR LIGANDS | Wyeth (US) | 2006-02-01 | — | — | EP | claimed |
| US-20050256132-A1 | Use of ER selective NF-kB inhibitors for the treatment of sepsis | WYETH (US) | 2005-11-17 | — | — | US | claimed |
| WO-2004099150-A2 | 3-(1-NAPHTHYL)-2-CYANOPROPANOIC ACID DERIVATIVES AS ESTROGEN RECEPTOR LIGANDS | WYETH (US) | 2004-11-18 | — | — | WO | claimed |
| EP-3551623-B1 | ORGANIC ELECTROLUMINESCENT COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAME | ROHM & HAAS ELECT MATERIALS KOREA LTD (KR) | 2021-09-22 | — | — | EP | disclosed |
| WO-2021012659-A1 | COMPOUND WITH ANDROGEN RECEPTOR DEGRADATION ACTIVITY | 上海美志医药科技有限公司 | 2021-01-28 | — | — | WO | disclosed |
| EP-3386987-B1 | ORGANIC ELECTROLUMINESCENT COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAME | ROHM & HAAS ELECT MATERIALS KOREA LTD (KR) | 2020-04-15 | — | — | EP | disclosed |
| EP-3322693-B1 | A PLURALITY OF HOST MATERIALS AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAME | ROHM & HAAS ELECT MATERIALS KOREA LTD (KR) | 2020-02-12 | — | — | EP | disclosed |
| WO-2019066258-A1 | ORGANIC ELECTROLUMINESCENT COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAME | ROHM AND HAAS ELECTRONIC MATERIALS KOREA LTD. (KR) | 2019-04-04 | — | — | WO | disclosed |
| WO-2018066812-A1 | ORGANIC ELECTROLUMINESCENT COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAME | ROHM AND HAAS ELECTRONIC MATERIALS KOREA LTD. (KR) | 2018-04-12 | — | — | WO | disclosed |
| WO-2017200210-A1 | ORGANIC ELECTROLUMINESCENT COMPOUND, ORGANIC ELECTROLUMINESCENT MATERIAL AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING THE SAME | ROHM AND HAAS ELECTRONIC MATERIALS KOREA LTD. (KR) | 2017-11-23 | — | — | WO | disclosed |
| US-20070299105-A1 | 2-Cyanopropanoic Acid Amide and Ester Derivatives and Methods of Their Use | WYETH (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070259951-A1 | Compounds, Compositions and Methods | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-08 | — | — | US | disclosed |
| EP-1694281-A2 | BIPHENYL COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-30 | — | — | EP | disclosed |
| EP-1620102-A2 | 3-(1-NAPHTHYL)-2-CYANOPROPANOIC ACID DERIVATIVES AS ESTROGEN RECEPTOR LIGANDS | Wyeth (US) | 2006-02-01 | — | — | EP | disclosed |
| US-20050256132-A1 | Use of ER selective NF-kB inhibitors for the treatment of sepsis | WYETH (US) | 2005-11-17 | — | — | US | disclosed |
| WO-2005060692-A2 | BIPHENYL COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-07-07 | — | — | WO | disclosed |
| US-20050004164-A1 | 2-Cyanopropanoic acid amide and ester derivatives and methods of their use | WYETH | 2005-01-06 | — | — | US | disclosed |
| WO-2004099150-A2 | 3-(1-NAPHTHYL)-2-CYANOPROPANOIC ACID DERIVATIVES AS ESTROGEN RECEPTOR LIGANDS | WYETH (US) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256132-A1 | Use of ER selective NF-kB inhibitors for the treatment of sepsis | NFKBIA, IKBKB, NFKB2 | CYP3A4 1729/4885ALDH1A1 4483/4885TDP1 4290/4885 |
| US-20070299105-A1 | 2-Cyanopropanoic Acid Amide and Ester Derivatives and Methods of Their Use | HCAR2, PCCA, MCCC2 | CYP3A4 3147/4885ALDH1A1 1159/4885TDP1 3732/4885 |
| US-20070259951-A1 | Compounds, Compositions and Methods | ALPP, PCNA, MKI67 | CYP3A4 4658/4885ALDH1A1 2715/4885TDP1 918/4885 |
| US-20050004164-A1 | 2-Cyanopropanoic acid amide and ester derivatives and methods of their use | HCAR2, PCCA, MCCC2 | CYP3A4 3187/4885ALDH1A1 1172/4885TDP1 3741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.